Aratana Therapeutics (NASDAQ:PETX)‘s stock had its “hold” rating restated by Stifel Nicolaus in a report released on Monday. They currently have a $6.00 price objective on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective would suggest a potential upside of 11.73% from the company’s current price.

Several other brokerages also recently commented on PETX. Lake Street Capital cut their price target on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 25th. ValuEngine downgraded shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Jefferies Group reiterated a “buy” rating and set a $8.00 price target on shares of Aratana Therapeutics in a report on Friday, November 3rd. Zacks Investment Research upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a report on Thursday, November 9th. Finally, HC Wainwright started coverage on shares of Aratana Therapeutics in a report on Friday, November 17th. They set a “buy” rating and a $10.00 price target on the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $8.55.

Shares of Aratana Therapeutics (PETX) opened at $5.37 on Monday. Aratana Therapeutics has a fifty-two week low of $4.97 and a fifty-two week high of $8.63. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The firm had revenue of $6.16 million for the quarter, compared to the consensus estimate of $6.47 million. During the same period in the previous year, the firm posted ($0.38) EPS. The business’s quarterly revenue was up 1440.0% on a year-over-year basis. research analysts expect that Aratana Therapeutics will post -1.03 EPS for the current year.

In other Aratana Therapeutics news, COO Brent Standridge sold 10,000 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $6.11, for a total value of $61,100.00. Following the transaction, the chief operating officer now directly owns 70,267 shares in the company, valued at approximately $429,331.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $5.70, for a total transaction of $5,075,941.20. The disclosure for this sale can be found here. Insiders have sold a total of 1,117,032 shares of company stock worth $6,559,891 over the last quarter. 5.20% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of PETX. Janus Henderson Group PLC bought a new position in Aratana Therapeutics in the 2nd quarter worth about $12,948,000. Broadfin Capital LLC lifted its position in shares of Aratana Therapeutics by 40.3% in the 2nd quarter. Broadfin Capital LLC now owns 5,184,942 shares of the biopharmaceutical company’s stock worth $37,487,000 after purchasing an additional 1,489,500 shares during the period. Franklin Resources Inc. lifted its position in shares of Aratana Therapeutics by 11.2% in the 2nd quarter. Franklin Resources Inc. now owns 6,011,309 shares of the biopharmaceutical company’s stock worth $43,462,000 after purchasing an additional 604,518 shares during the period. AWM Investment Company Inc. lifted its position in shares of Aratana Therapeutics by 49.4% in the 2nd quarter. AWM Investment Company Inc. now owns 1,587,620 shares of the biopharmaceutical company’s stock worth $11,478,000 after purchasing an additional 525,000 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Aratana Therapeutics by 197.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 380,895 shares of the biopharmaceutical company’s stock worth $2,754,000 after purchasing an additional 252,655 shares during the period. Institutional investors and hedge funds own 73.76% of the company’s stock.

WARNING: This article was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.watchlistnews.com/stifel-nicolaus-reiterates-hold-rating-for-aratana-therapeutics-petx/1773646.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.